Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH
Yuki Kimura(Jichi Medical University), Kazuaki Chayama(RIKEN Center for Integrative Medical Sciences), Hideyuki Hyogo(Albert Einstein College of Medicine), Sho‐ichi Yamagishi(Kurume University), Tomokazu Ishitobi(Hiroshima University), Koji Arihiro(Hiroshima University Hospital), Yoshitaka Nabeshima(Hiroshima University), Masayoshi Takeuchi(Kanazawa Medical University)
Cited by 160
Related Papers
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
A proposed system for the nomenclature of hepatitis C viral genotypes
|Hepatology|1994|1k
Endothelial Cells Are Essential for the Self-Renewal and Repopulation of Notch-Dependent Hematopoietic Stem Cells
|Cell stem cell|2010|670